## Abstract In this work, magnetite (Fe~3~O~4~) nanoparticles with an average size 10 nm modified by sodium oleate were prepared by the modified controlled chemical coprecipitation method, which can be well dispersed in water and linked well with protein molecules because of the presence of —COOH o
Preparation and Characterization of Biodegradable Microspheres Containing Hepatitis B Surface Antigen
✍ Scribed by Shaobing Zhou; Xueyan Liao; Zhenglun Liang; Xiaohong Li; Xianmo Deng; Heming Li
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 161 KB
- Volume
- 4
- Category
- Article
- ISSN
- 1616-5187
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Summary: Poly‐DL‐lactide‐poly(ethylene glycol) (PELA) microspheres containing Hepatitis B surface antigen (HBsAg) were elaborated by a solvent extraction method based on the formation of a double water/oil/water (w/o/w) emulsion. Microspheres were characterized in terms of morphology, size and size distribution, encapsulation efficiency, and the efficiency of microsphere formation (EMF). Transmission electron microscopy (TEM) and polyacrylamide gel electrophoresis (PAGE) were used to investigate the structural integrality of HBsAg encapsulated in PELA microspheres. The release profile was investigated by the measurement of antigen present in the release medium at various intervals. The PELA‐10 microspheres displayed the highest antigen encapsulation efficiency (about 80%), and antigen molecules could be stabilized in the PELA‐10 microspheres during the preparation process. It suggested that the PELA microspheres had a great potential as a new polymer adjuvant for HBsAg.
The release of Hepatitis B surface antigen from poly‐DL‐lactide‐poly(ethylene glycol) microspheres.
imageThe release of Hepatitis B surface antigen from poly‐DL‐lactide‐poly(ethylene glycol) microspheres.
📜 SIMILAR VOLUMES
## Abstract Antibody to hepatitis B surface antigen (HBsAg) (anti‐HBs) can exist in patients with chronic hepatitis B virus (HBV) infection. To date, little is known about the association of concurrent HBsAg and anti‐HBs (concurrent HBsAg/ anti‐HBs) with hepatocellular carcinoma (HCC). The aim of t
Hepatitis B virus infects about 200 million people worldwide yearly. The consequences of the infection range from mild, sew-limiting hepatitis with full recovery and immunity to chronic infection with liver disease of varying severity, including fulminant hepatitis and death. Alternatively, individu
## Abstract Small hepatitis B surface antigen (HBsAg) is considered to be the best marker for the diagnosis of Hepatitis B virus infection. However, HBsAg variants with mutations within the “a” determinant may be poorly or not detected by diagnostic assays. Three anti‐HBsAg monoclonal antibodies (6
Quantitative hepatitis B surface antigen (qHBsAg) and quantitative hepatitis B e antigen (qHBeAg) titers are emerging as useful tools for measuring viral loads and for predicting the virological response (VR) and serological response (SR) to pegylated interferon therapy. However, the clinical utilit